Phase II Fludarabine and Cytoxan + FCCam in Untreated B-Cell CLL

Trial ID or NCT#

NCT00230282

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.

Official Title

A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Contact us to find out if this trial is right for you.

Contact

Nini Estevez
6507254041

View on ClinicalTrials.gov